Literature DB >> 8407980

Purification and characterization of endothelin-converting enzyme from rat lung.

M Takahashi1, Y Matsushita, Y Iijima, K Tanzawa.   

Abstract

Endothelin-converting enzyme, a key enzyme in the production of a potent vasoconstricting peptide, endothelin, was purified to homogeneity from rat lung microsomes. A sensitive and convenient assay method using the 125I-endothelin-1 receptor binding assay was developed for purification studies. The enzyme was solubilized with Triton X-100 and was purified at high yield by sequential column chromatography on wheat germ agglutinin-agarose, zinc-chelating Sepharose, and Blue Bagarose. Electrophoretic analysis of the purified enzyme revealed one protein band with M(r) 130,000. High performance liquid chromatographic analysis of the enzyme reaction revealed that purified enzyme quantitatively converted big endothelin-1 to endothelin-1, indicating that the enzyme specifically cleaved the bond between Trp21 and Val22. The enzyme was inhibited by metal chelators and phosphoramidon, but not by thiorphan and captopril. Lung endothelin-converting enzyme preferred big endothelin-1 to big endothelin-2 or -3 as a substrate, and kinetic analysis revealed that the Michaelis constant and a maximal velocity for big endothelin-1 were 0.20 microM and 3.1 nmol/min.mg protein, respectively. Lung endothelin-converting enzyme is a typical neutral metalloproteinase and is similar to the enzyme from endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407980

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

Review 4.  The Second Gaddum Lecture: its origins and outcomes.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2020-02-05       Impact factor: 8.739

5.  Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11.

Authors:  K Shimada; M Takahashi; A J Turner; K Tanzawa
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

Review 6.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

7.  Differential gene expression in mouse retina related to regional differences in vulnerability to hyperoxia.

Authors:  Yuan Zhu; Riccardo Natoli; Krisztina Valter; Jonathan Stone
Journal:  Mol Vis       Date:  2010-04-28       Impact factor: 2.367

8.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

9.  Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to control receptor recycling.

Authors:  Dirk Roosterman; Graeme S Cottrell; Benjamin E Padilla; Laurent Muller; Christopher B Eckman; Nigel W Bunnett; Martin Steinhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.